Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage 1 Hypertension Clear all
Completed Phase 1 Interventional

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

NCT00638742
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 29, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

NCT03370991
View directory record Official record
Conditions
Menopause, Elevated Blood Pressure, Hypertension, Endothelial Dysfunction
Interventions
Blueberry Powder, Placebo Powder
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

NCT05961397
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Rialto, California • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

NCT06413251
View directory record Official record
Conditions
Elevated Blood Pressure, Hypertension
Interventions
Boxing Training, Control flexibility
Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 29, 2026, 5:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07675824
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
REGN22530
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

NCT00662610
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01528111
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Not applicable Interventional

The Penn Lifestyle Modification and Blood Pressure Study

NCT00328666
View directory record Official record
Conditions
Hypertension
Interventions
Iyengar yoga, Enhanced nutritional care classes
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 29, 2026, 5:11 AM EDT
Not listed Phase 4 Interventional

Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension

NCT04908982
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Aspirin 81mg
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

NCT00662896
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

NCT05798481
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 29, 2026, 5:11 AM EDT
Active, not recruiting Not applicable Interventional

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

NCT05372679
View directory record Official record
Conditions
Uncontrolled Stage 2 Hypertension
Interventions
Renal denervation
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Weight Inclusive and Adaptive Strategies to Enhance Cardiometabolic Health in Black Adults

NCT06284681
View directory record Official record
Conditions
Obesity, Prehypertension, Hypertension, PreDiabetes, Type 2 Diabetes, Dyslipidemia
Interventions
Weight-focused health coaching, Weight-neutral health coaching, Intensify lifestyle approach, Augment with enhanced medical management
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

NCT00527514
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine, Olmesartan medoxomil plus amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840
View directory record Official record
Conditions
Prehypertension, Hypertension, Stage I
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tustin, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 29, 2026, 5:11 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PF-07868489, Placebo for PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
16
States / cities
Anaheim, California • Costa Mesa, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 5:11 AM EDT
Suspended Phase 1Phase 2 Interventional

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04761705
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
JV-GL1, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
JeniVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 29, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925
View directory record Official record
Conditions
Hypertension
Interventions
PS433540, placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 29, 2026, 5:11 AM EDT